1. A method for screening, constructing, developing or otherwise producing a therapeutic agent effective for treating a transglutaminase-associated disorder, disease and / or condition, wherein said method comprises the step of determining whether the candidate agent is capable of modulating the interaction between (i) TG and IGF； and / or (ii) TG and a member of the IGF.2 receptor family. The method of claim 1, wherein the IGF is selected from IGF-I and IGF-II. The method of claim 2, wherein the IGF is IGF-I.4. The method of claim 1, wherein the member of the IGF receptor family is selected from the group consisting of IGF-1R, an insulin receptor, an insulin receptor-related receptor, and a hybrid IGF insulin receptor. The method of claim 4, wherein the member of the IGF receptor family is selected from the group consisting of IGF-1R, an insulin receptor, and a hybrid IGF insulin receptor. The method of claim 5, wherein the member of the IGF receptor family is selected from IGF-1R and a hybrid IGF-insulin receptor. The method of claim 6, wherein the member of the IGF receptor family is IGF-1R.8. The method of claim 1, wherein the TG is selected from the group consisting of FXIII, TG1, TG2, TG3, TG4, TG5, TG6, and TG7.9. The method of claim 1, wherein the TG is selected from FXIII and TG2.10. The method of claim 9, wherein the TG is TG2.11. The method of claim 1, wherein said candidate agent is a modulator selected from the group consisting of an isolated peptide, an isolated polypeptide, an antibody, an isolated nucleic acid, and a small organic molecule. The method of claim 11, wherein said antibody is a monoclonal antibody. The method according to claim 11, according to1. Способ скрининга, конструирования, разработки или иного пути продуцирования терапевтического средства, эффективного для лечения ассоциированного с трансглутаминазой расстройства, заболевания и/или состояния, где указанный способ включает стадию определения того, способно ли средство-кандидат мод
